

BOARD OF PHARMACY
Professional & Vocational Licensing Division
Department of Commerce and Consumer Affairs
State of Hawaii

MINUTES OF MEETING

Date: Thursday, April 20, 2017

Time: 9:00 a.m.

Place: Queen Liliuokalani Conference Room
King Kalakaua Building
335 Merchant Street, First Floor
Honolulu, Hawaii 96813

Members Present: Marcella Chock, PharmD., Pharmacist
Garrett Lau, RPh, Vice Chair, Pharmacist
Carolyn Ma, PharmD., BCOP, Pharmacist
Mary Jo Keefe, RPh, Pharmacist
Ronald Weinberg, Public

Members Excused: Kerri Okamura, RPh, Chair, Pharmacist
Julie Takishima-Lacasa, PhD, Public

Staff Present: Lee Ann Teshima, Executive Officer ("EO")
Shari Wong, Deputy Attorney General ("DAG")
Lisa Kalani, Secretary

Guests: Kellie Noguchi, Times
Dean Yamamoto, Dept. of Public Safety Narcotics Enforcement Div.
Paul Smith, Walgreens
Fred Cruz, CVS Caremark
Tiffany Yajima, Ashford & Wriston LLP
Stacy Pi, Kaiser Permanente
Catalina Cross, Times
Patrick Uyemoto, Times
Joe Parrott, Walmart
Seth Corpuz

Call to Order: The agenda for this meeting was filed with the Office of the Lieutenant Governor, as required by section 92-7(b), Hawaii Revised Statutes ("HRS").

There being a quorum present, the Vice Chair called the meeting to order at 9:00 a.m. and excused the Chair and Dr. Takishima-Lacasa from today's meeting.

Vice Chair's Report: **Announcements and Introductions**

The Vice Chair asked the audience to introduce themselves.

Approval of the Previous Minutes – February 16, 2017 Meeting

The Vice Chair called for a motion in regards to the minutes of the February 16, 2017 meeting.

There being no discussion, upon a motion by Mr. Weinberg, seconded by Ms. Keefe, it was voted on and unanimously carried to approve the minutes for the February 16, 2017 meeting as circulated.

Executive Officer's Report:

Conferences/Seminars/Meetings

The EO reported on April 1, 2017, she and Jared Redulla from the Department of Public Safety, Narcotics Enforcement Division did a joint presentation at the Hawaii Pharmacists Association (HPhA) annual meeting. They went over the corresponding responsibility document and legislative matters. She did encourage HPhA to work together with the Board on legislative matters and that educating the legislators and other stakeholders is very vital.

ACPE Evaluation Team Site Visit at the University of Hawaii Daniel K. Inouye, College of Pharmacy, March 7-9, 2017, Hilo, Hawaii

The EO reported the Chair attended and will give a report at the next meeting.

MPJE Item Development Workshop, March 14-16, 2017, Northbrook, Illinois

The EO reported the Chair attended and will give a report at the next meeting.

NABP's 113th Annual Meeting – May 20-23, 2017, Orlando, Florida

The EO reported that Ms. Keefe will be attending

2017 Legislative Session

The EO reported on the status of the following bills:

- HB 676, HD1/SB 514, SD1, HD1 Relating to Health (HPV)
HB 676, HD1 is dead. SB 514, SD1, HD1 is scheduled for conference hearing tomorrow. Either house can agree or disagree to the amendments made to its bill by the non-originating house. If either house chooses to disagree such bills may be referred to a conference committee for further consideration of areas of disagreement.

- HB 675 /SB 513, SD1, HD2 Relating to Contraceptive Supplies
HB 675 is dead. SB 513, SD1, HD2 is scheduled for conference committee hearing tomorrow.
- HB 527, HD1, SD2/SB 347, SD1, HD1 Relating to Mobile Clinics
HB 527, HD1, SD2 is scheduled for conference committee hearing tomorrow. SB 347, SD1, HD1 is dead.
- HB 1299, HD1, SD1 Relating to Health (Customized packaging)
This bill is scheduled for conference committee hearing tomorrow.
- HB 1444, HD2, SD2/SB 1158, SD1 Relating to Pharmacy Benefit Managers
Both bills are scheduled for conference committee hearing tomorrow.
- HB 667, HD1/SB 505, SD1, HD2 Relating to Health (Informed consent to opioid therapy)
HB 667, HD1 is dead. SB 505, SD1, HD2 is scheduled for conference committee hearing tomorrow.
- HB1131/SB 997, SD1, HD2 Relating to the Uniform Controlled Substances Act
HB 1131 is dead. SB 997, SD1, HD2 is scheduled for conference committee hearing tomorrow.

The EO reported the following bills are dead:

- SB 1223, SD1 Relating to Homelessness
- SB 357 Relating to Aid in Dying
- HB 150 Relating to End of Life Option
- SB 1129, SD2 Relating to Health (Aid in dying)
- HB 197/SB 1080 Relating to Administering, Dispensing, or Prescribing Narcotic Drugs for Use in Maintenance or Detoxification Treatment to a Narcotic Dependent Person
- SB 190 SD1 Relating to the Controlled Substances Act
- HB 797 Relating to Pharmacists
- HB 1132, HD1/SB 998 Relating to the Uniform Controlled Substances Act
- HB 666/SB 504 Relating to Controlled Substances
- HB 1316/SB 868, SD1 Relating to the Controlled Substances Act
- HB 767, HD1/SB 384, SD2, HD1 – Relating to Prescriptive Authority for Certain Clinical Psychologists
- SB 223, SD2, HD1 Relating to Naturopathic Medicine
- SB 187 Relating to Pharmacists (Practice of clinical pharmacy)
- HB 370 Relating to Pharmacy (Outsourcing facilities)
- SB 191 Relating to Health Care Practitioner Transparency

Naloxone Collaborative Practice

Criteria for Collaborative Practice Agreement

The Vice Chair suggested forming a working group to come up with the criteria for a collaborative practice agreement (CPA) and encouraged interested parties to participate.

The EO stated this needs to be done as soon as possible. She stated the Board had previously looked at a CPA from CVS and believes Walgreens also has one that they use nationally. She addressed the audience and stated that she would like the working group to consist of 2 board members, and representation from regular audience members such as CVS, Walgreens, Kaiser, HPhA, Times, Walmart, and also the Department of Health. She would like to meet after the Board's next meeting and asked those who already have a CPA for dispensing naloxone to share it with the members of the working group so that they can use elements from the various agreements to create a list of criteria. The goal of the working group is to come up with a list of criteria for the CPA for the Board's consideration.

The following will be participating in the working group and will be meeting after the May Board meeting:

- Fred Cruz or representative from CVS
- Paul Smith, Pharmacist
- Patrick Uyemoto, HPhA and Times
- Stacy Pi, Kaiser
- Joe Parriott, Walmart
- Tiffany Yajima, Walgreens
- Peter Whitaker or representative from Department of Health
- Chair and Vice Chair from the Board of Pharmacy

Inquiry from Stacy Pi, Kaiser

The Board reviewed an email from Stacy Pi with the following questions. The Boards responses follow each question.

1. Will the Board be drafting a collaborative agreement for opioid antagonists, similar to how it did for Emergency Contraception? *The Board will be coming up with criteria to be included in a CPA to dispense naloxone, but not an actual form.*
2. If so, what's the anticipated timeline? *2-3 months.*
3. Do you know what the Medical Board's stance on this issue is? *No.*
4. Do the following examples meet the pharmacist training requirements? *As long as it is ACPE approved.*

Professional Development

The Board reviewed the following Professional Development articles:

- Balanced Living, March 2017
- Working Solutions, March 2017

Correspondence:

National Association of Boards of Pharmacy ("NABP")

The Vice Chair asked Dr. Chock to lead the discussion on the following:

- Congress Legislation to Allow Americans to Purchase Prescription Medications from Canada

Ms. Melissa Madigan, NABP's Policy and Communications Director on behalf of NABP reached out to the Board via email to ask for help to educate members of Congress about the patient safety risks posed by recently introduced federal legislation that would permit Americans to purchase prescription medication from Canada. NABP is extremely concerned about the impact this new legislation would have on patient safety. NABP humbly offered a draft letter and infographic for the Board's consideration to send to Congress, specifically Senator Mazie Hirono, [D-H], as is or adapted to fit the specifics of our state.

The Vice Chair asked Ms. Keefe to lead the discussion on the following:

- Clarification of Model Act Language Pertaining to Licensure Exemption for Facilities That Solely Distribute Dialysate, Drugs, or Devices for Home Dialysis
- NABP sent correspondence elaborating on the history and reasoning behind the licensure exemption for facilities that solely distribute dialysate, drugs, or devices to patients for home dialysis, which is found in Article V, Licensing of Facilities, of The Model State Pharmacy Act and Model Rules of the National Association of Boards of Pharmacy (Model Act). The current language gives a board of pharmacy the option to consider this type of licensure exemption. The language is not intended to make the licensure exemption mandatory. Additionally, it contains specific provisions that maintain patient safety and the integrity of the drug distribution system explicitly for the administration of the dialysate and should not be applied to other, unrelated medications. NABP unwaveringly supports the prohibition of direct-to-patient delivery of medications beyond the limited scope of the exemption.

Article V Licensing of Facilities, Section 501. Licensing states, in part:

- (j) The Board may consider exempting facilities engaged solely in the distribution of dialysate, drugs or devices necessary to perform home renal dialysis to patients with chronic kidney failure from pharmacy licensure, provided that the following criteria are met:

- (1) The dialysate, drugs or devices are approved by the Food and Drug Administration, as required by Federal Law.
- (2) The dialysate, drugs or devices are lawfully held by a manufacturer (or a manufacturer's agent) that is properly registered with the Board as a manufacturer and/or wholesale drug distributor
- (3) The dialysate, drugs or devices are held and delivered in their original, sealed labeled packaging from the manufacturing facility.
- (4) The dialysate, drugs or devices are delivered only by the manufacturer (or the manufacturer's agent) and only upon receipt of a physician's order.
- (S) The manufacturer (or manufacturer's agent) delivers the dialysate, drugs, or devices directly to:
 - (A) a patient with chronic kidney failure, or his/her designee, for the patient's self-administration of dialysis therapy, or
 - (B) a health care provider or institution for administration or delivery of the dialysis therapy to a patient with chronic kidney failure.
- (6) Records of all sales and distribution of dialysate, drugs or devices to home dialysis patients must be retained and readily available for inspection and copying by the Board for ___ years.

The EO stated she does not agree with their exemption. At the very least they should be required to have a Miscellaneous Permit.

The Vice Chair led the discussion on the following:

➤ Food and Drug Administration's Continuing Education Webinars

The Board received correspondence from NABP announcing that the Food and Drug Administration (FDA) Center for Drug Evaluation and Research, Division of Drug Information is presenting a series of continuing education webinars targeted toward health care professionals and future clinicians to provide better patient care by knowing how to find relevant FDA regulatory information that will improve drug safety. For more information and to learn about future webinars, please visit: www.fda.gov/DDIWebinars.

The Vice Chair asked Dr. Ma to lead the discussion on the following:

➤ National Working Group Develops Pharmacist Statewide Protocol Policy Recommendations to Improve Patient Access

The Statewide Protocol Workgroup, convened by the National Alliance of State Pharmacy Associations (NASPA) and the NABP, has developed policy recommendations for pharmacist statewide protocols. These recommendations include the key elements that should be included in state laws and regulations authorizing the development of statewide protocols, including the components that should be included in the protocol

itself. Statewide protocols are sometimes compared to or equated with collaborative practice agreements, however the substantive difference is that statewide protocols are issued by an authorized state regulatory body, whereas collaborative practice agreements are developed and implemented between individual or groups of prescribers and pharmacists. Because statewide protocols facilitate pharmacists' ability to perform patient care services, within defined parameters, they can be used by states to address significant public health needs. For example, access to vaccines, naloxone for opioid overdose, and hormonal contraceptives.

The Vice Chair asked Dr. Chock to lead the discussion on the following:

➤ March 2017 State Newsletters - Idaho – Streamlining Medication Synchronization

The goal of medication synchronization is to align the refill dates of a patient's prescription medications, which creates substantial convenience benefits for patients and has been shown to improve medication adherence rates. In Idaho, updates to Rule 116 sought to remove the administrative burden placed on pharmacists and prescribers when synchronizing a patient's medications. Specifically, if a patient opts in to a medication synchronization program, a pharmacist could use his or her judgment to extend a maintenance drug beyond the quantity initially authorized by the prescriber for the purpose of coordinating a patient's refills. Importantly, the ability to extend may not be exercised in the case of controlled substances, compounded drugs, or biological products.

The EO stated there is a House concurrent resolution requesting that the Department of Health establish a medication synchronization working group to explore proposed legislation for next year.

Joint Commission's New Medication Compounding Certification Program

The Vice Chair asked Ms. Keefe to lead the discussion on the Joint Commission's new Medication Compounding Certification program. The basis for the Joint Commission standards are the sterile and non-sterile compounding requirements issued by the United States Pharmacopeia (USP) in its chapters <797> and <795>. The aim of the certification program is to perform an in-depth assessment of a specific set of standards that uniquely reflects the preparation and dispensing of sterile and/or unsterile products in accordance with USP <795> and <797>. To maintain certification, an organization must undergo an onsite review at least once every two years, where compliance with the standards will be assessed by a pharmacist surveyor that has undergone specific training in evaluating compliance with USP requirements.

Some of the benefits of State Reliance on Certification are as follows:

- Provides an independent third party evaluation of a compounding pharmacy's practices

- Provides assurance that pharmacies are compliant with state regulations/USP requirements
- Flexibility to update standards in timely manner- when the proposed chapter <797> revisions are finalized, and chapter <800> becomes effective, the Joint Commission standards will be updated accordingly
- Allows state pharmacy boards the ability to direct limited resources toward other oversight activities
- Reduction in the number of inspections per year – eliminates redundancy
- Increased communication between all parties

For more information on the program, you may visit their website at:

<https://www.jointcommission.org/certification/mdcbop.aspx>

Professional Boundaries Inc.'s "Pharmacy Ethics and Professionalism Course"

The Vice Chair led the discussion on an email from Cindy Boling, Director of Communications and Regulatory Board Liaison at Professional Boundaries, Inc. (PBI). PBI is a provider of the remedial Pharmacy Ethics and Professionalism Course. The course is a resource for the board and for licensees facing disciplinary action for ethics, boundaries, and professionalism violations. Each PBI course is specific as to state laws and rules, medical specialty specific, and violation specific.

The EO stated the reason she brought this to the attention of the Board is because when the Regulated Industries Complaints Office negotiates a settlement for ethical or professional boundaries, they could include a course that the Board has already approved, instead of saying a "Board approved course".

Health Day Article "Opioid Dependence Can Start in Just a Few Days"

The Vice Chair asked Dr. Ma to lead the discussion on an article from Health Day News. The article states, doctors who limit the supply of opioids they prescribe to three days or less may help patients avoid the dangers of dependence and addiction, a new study suggests. Among patients without cancer, a single day's supply of a narcotic painkiller can result in 6 percent of patients being on an opioid a year later, the researchers said. The odds of long-term opioid use increased most sharply in the first days of therapy, particularly after five days of taking the drugs. The rate of long-term opioid use increased to about 13 percent for patients who first took the drugs for eight days or more, according to the report. Awareness among prescribers, pharmacists and persons managing pharmacy benefits, that authorization of a second opioid prescription doubles the risk for opioid use one year later might deter overprescribing of opioids. The chances of long-term opioid use, use that lasts one year or more, start increasing with each additional day supplied, starting after the third day, and increase substantially after someone is prescribed five or more days, and especially after someone is prescribed one month of opioid therapy.

The odds of chronic opioid use also increase when a second prescription is given or refilled. People starting on a long-acting opioid or tramadol (Ultram) were more likely to stay on opioids than those given hydrocodone (Vicodin) or oxycodone (Oxycontin). The highest probability of continued opioid use at one and three years was seen among patients who started on a long-acting opioid, followed by patients who started on tramadol.

Star Advertiser Article “Involve pharmacists on medical cannabis”

The Vice Chair led the discussion on a Star Advertiser Article titled “Involve pharmacists on medical cannabis” written by Anne Wheelock of Honolulu, who has been a community retail pharmacist in Hawaii since 1981. The article states that pharmacists should take a more active role in learning about medical marijuana and its uses. Medical cannabis is supplied through licensed, registered dispensaries, not pharmacies, but, the author would propose that pharmacists are the health care providers best equipped to care for medical cannabis patients.

The EO asked if medical cannabis is taught in pharmacy school?

Dr. Ma stated yes, in some ways.

The EO asked if a pharmacist would know which cannabis strain is most effective for a patient’s condition?

Dr. Ma replied no. She stated first of all because it is a Schedule I, it is illegal from a Federal standpoint for a pharmacist to handle it. Right now the only dispensary she knows of that has a pharmacist on staff is on the big island. The pharmacist is not in the dispensary, but off to the side in another room to provide counseling on cannabis interaction with other medications.

Affiliated Monitors, Inc. “Monitoring: A Remedial Approach to Improvement”

The Vice Chair led the discussion on correspondence from Affiliated Monitors, Inc. Affiliated Monitors, Inc. provides independent monitoring services with regulatory agencies in 27 states including Board of Medicine, Dentistry, Pharmacy, Chiropractic, Physical Therapy, Funeral Homes and other regulated professions. They also work with insurance companies to provide independent monitoring of network providers and in Medicaid and Medicare Fraud matters to provide independent oversight of practice compliance with government and industry standards. This service allows practitioners to remain in practice or in-network for infractions that can be remediated through third-party, professional oversight.

Executive Session:

At 9:48 a.m. upon a motion by the Vice Chair, seconded by Mr. Weinberg, it was voted on and unanimously carried to move into Executive Session in accordance with HRS, 92-5(a)(4), “To consult with the board’s attorney on questions and issues pertaining to the board’s powers, duties, privileges, immunities, and liabilities”.

At 10:17 a.m. upon a motion by the Vice Chair, seconded by Dr. Chock, it was voted on and unanimously carried to move out of executive session.

Chapter 91, HRS,
Adjudicatory Matters:

The Vice Chair called for a recess from the meeting at 10:21 a.m. to discuss and deliberate on the following adjudicatory matter(s) pursuant to Chapter 91, HRS:

In the Matter of the Pharmacy Permit of **Queen's Development Corp. dba Queen's POB II Pharmacy** and the Pharmacist License of **Eunice M. Chong; PHA 2016-101-L**, Settlement Agreement Prior to Filing of Petition for Disciplinary Action and Board's Final Order.

Upon a motion by Ms. Keefe, seconded by Mr. Weinberg, it was voted on and unanimously carried to approve the Board's Final Order.

In the Matter of the Miscellaneous Permit of **Ameripharm, Inc., dba Medvantx Specialty Pharmacy; PHA 2016-118-L**, Settlement Agreement Prior to Filing to Petition for Disciplinary Action and Board's Final Order; Exhibit "1".

Upon a motion by Dr. Ma, seconded by the Vice Chair, it was voted on and unanimously carried to approve the Board's Final Order.

In the Matter of the Miscellaneous Permit of **Avella of Orlando, Inc., dba Avella of Orlando; PHA 2016-79-L**, Settlement Agreement Prior to Filing of Petition for Disciplinary Action and Board's Final Order; Exhibits "1" and "2".

Upon a motion by Mr. Weinberg, seconded by Ms. Keefe, it was voted on and unanimously carried to approve the Board's Final Order.

Following the Board's review, deliberation, and decisions in this matter, pursuant to Chapter 91, HRS, the Chair announced that the Board was reconvening its scheduled meeting at 10:21 a.m.

Applications:

Ratification List

Upon a motion by the Vice Chair, seconded by Mr. Weinberg, it was voted on and unanimously carried to approve the attached ratification lists.

Pharmacist(s)

Upon a motion by Mr. Weinberg, seconded by the Vice Chair it was voted on and carried to approve the following:

Kyle Reynolds

Upon a motion by Mr. Weinberg, seconded by Ms. Keefe it was voted on and carried to approve the following:

Jason Lewis

Miscellaneous Pharmacy Permits (PMPs)

Upon a motion by Mr. Weinberg, seconded by Ms. Keefe, it was voted on and unanimously carried to approve the following:

Factor Support Network Pharmacy, Inc.

Upon a motion to approve by Mr. Weinberg, seconded by the Vice Chair, and opposed by Dr. Ma and Dr. Chock, it was voted on and the motion failed. The following is deferred:

Pharmcore, Inc., dba Hallandale Pharmacy

Upon a motion by Dr. Ma, seconded by Mr. Weinberg, it was voted on and unanimously carried to approve the following:

Vintage Pharmacy Plus LLC

Next Meeting: The Vice Chair announced that the next Board meeting is scheduled for May 18, 2017.

Dr. Ma and Dr. Chock stated they will not be able to attend the May meeting.

Thursday, May 18, 2017
9:00 a.m.
Queen Liliuokalani Conference Room
King Kalakaua Building
335 Merchant Street, First Floor
Honolulu, Hawaii 96813

Adjournment: With no further business to discuss, the Vice Chair adjourned the meeting at 10:28 a.m.

Taken and recorded by:

Reviewed and approved by:

/s/ Lisa Kalani
Lisa Kalani, Secretary

/s/ Lee Ann Teshima
Lee Ann Teshima, Executive Officer

4/28/17

[X] Minutes approved as is.
[] Minutes approved with changes; see minutes of _____

BOARD OF PHARMACY
April 20, 2017 Ratification List

Miscellaneous Permits (PMP)

Change of PIC

Bioscrip Infusion Services Inc. (PMP-1339)

199 Technology Dr. Ste. 140

Irvine, CA. 92618

New PIC: Norman Nagaishi

Effective: 2/6/17

Pharmedium Services LLC (PMP-575)

12620 West Airport Blvd. Ste. 130

Sugar Land, TX. 77478

New PIC: Bamidele Dauda Abdullahi

Effective: 2/14/17

Hartley Medical Center Pharmacy Inc. (PMP-607)

113 W Victoria St.

Long Beach, CA. 90805

New PIC: Amy Phan Trinh

Effective: 2/10/17

Avella of Orlando Inc. dba Avella of Orlando (PMP-1197)

100 Technology Park Ste. 155

Lake Mary, FL. 32746

New PIC: Mary Paula Stevens

Effective: 1/30/17

Med-Care Diabetic & Medical Supplies Inc. (PMP-678)

6500 E Rogers Circle Suite A

Boca Raton, FL. 33487

New PIC: Allen McSherry

Effective: 2/11/17

Praxis Specialty Pharmacy LLC dba Praxis Rx Pharmacy (PMP-1039)

5455 West Waters Ave. Ste. 214

Tampa, FL. 336324

New PIC: Arijit Aichbhaumik

Effective: 2/22/17

DQD Enterprise Corp dba Rx One Pharmacy (PMP-1286)

9740 Barker Cypress Rd. #107

Cypress, TX. 77433

New PIC: Catherine Loi

Effective: 3/1/17

Option Care Enterprises Inc. dba Option Care (PMP-725)

3920 W Charleston Blvd. #X
Las Vegas, NV. 89102
New PIC: Lizbeth Sharp
Effective: 3/28/17

**Kroger Specialty Pharmacy FL 2 LLC
dba Kroger Specialty Pharmacy FL 2 (PMP-740)**

6435 Hazeltine National Dr. Ste. 140
Orlando, FL. 32822
New PIC: Gerald Dawson
Effective: 3/31/17

**Kroger Specialty Pharmacy Inc.
dba Kroger Specialty Pharmacy CA 3 (PMP-1005)**

1021 Kaiser Ave.
Irvine, CA. 92614
New PIC: Tiffany Phung
Effective: 4/7/17

Closure/Cancellation

U S Specialty Care (PMP-279)

7472 South Tucson Way #100-B
Centennial, CO. 80112
Effective: 2/16/17

Liberty Medical LLC dba Liberty Medical Supply (PMP-506)

2157 Apperson Dr.
Salem, VA. 24153
Effective: 3/20/17

Mesa Pharmacy Inc. dba Mesa Pharmacy VII (PMP-705)

18013 Sky Park Cir #D
Irvine, CA. 92614
Effective: 4/30/17

Name/Trade Name Change

Kroger Specialty Pharmacy Inc. dba Kroger Specialty Pharmacy CA 3 (PMP-1005)

1821 Kaiser Ave.
Irvine, CA. 92614
Effective: 10/21/16

Kroger Specialty Pharmacy Inc. dba Kroger Specialty Pharmacy FL (PMP-171)

550 Technology Park
Lake Mary, FL. 32746
Effective: 10/21/16

Safeway Inc. dba Albertsons-Safeway Pharmacy #4705 (PMP-1275)

12874 E Florence Ave.
Santa Fe Springs, CA. 90670
Effective: 9/12/16

Relocation/Address Change

Sentrix Pharmacy and Discount LLC (PMP-1009)

3285 W. McNab Road

Pompano Beach, FL. 33069

Effective: 3/20/17

Pharmacy (PHY)

Change of PIC

Don Quijote (USA) Co Ltd dba Don Quijote Drugs (PHY-558)

94-144 Farrington Hwy.

Waipahu, HI. 96797

New PIC: Larry Tong

Effective: 3/2/17

Queen's Development Corporation dba Queen's POB I Pharmacy (PHY-470)

1300 Lusitana St.

Honolulu, HI. 96813

New PIC: Emerick Orimoto

Effective: 2/18/17

Queen's Development Corporation dba Queen's POB I Pharmacy (PHY-470)

1300 Lusitana St.

Honolulu, HI. 96813

New PIC: Greg Laurence Inoue

Effective: 3/13/17

Brian A. Carter Inc. dba The Kalaheo Pharmacy (PHY-891)

2436 Kaumualii Hwy.

Kalaheo, HI. 96741

New PIC: Jamie Caskey

Effective: 3/20/17

LTYPE	LIC NUM	BP NAME PART 1
PH	4135	CHANDNI P <WOODS<
PH	4136	THOMAS J <MATHEWS<
PH	4137	ALLAN T <HIGA<
PH	4138	MICHELLE A <PORTER<
PH	4139	LANCE M <CABANTING<
PH	4140	ELAINE M <LADD<
PH	4141	KAYDI E W <NG<
PH	4142	KATELYN E <COLE<
PH	4143	KAYLA M <REVERMANN<
PH	4144	LIZA D <NGUYEN<
PH	4145	GARY A <LUPINI<
PH	4146	SARAH S <HORNG<
PH	4147	MIRELA <NGO<

LTYPE	LIC NUM	BUSN ADDR 1	BUSN CITY	BUSN		BP NAME PART 1
				ST	BUSN ZIP	
PMP	1369	55 MITCHELL BLVD STE 11	SAN RAFAEL	CA	94903	MARIN WELLNESS PHARMACY INC
PMP	1370	DBA BETTER BALANCE PHARMACY	IRVINE	CA	92614	GORDIAN MEDICAL II INC
PMP	1371	5008 PETERS CREEK PARKWAY	WINSTON SALEM	NC	27127	MARLEY DRUG INC
PMP	1372	10607 &10611 AURORA AVE	URBANDALE	IA	50322	BIORX LLC
PMP	1373	9414 PARKFIELD DR #4	AUSTIN	TX	78758	FARMACIA LIBERTAD LLC
PMP	1374	9542 UNION GROVE RD	UNION GROVE	AL	35175	VETERINARY INTERNET COMPANY RETAIL PHARMACY
PMP	1375	150 CLEVELAND RD STE B	BOGART	GA	30622	PHARMACEUTICAL SPECIALTIES LLC
PMP	1376	5437 N BROADWAY AVE	CHICAGO	IL	60640	PHARMASCRIP INC
PMP	1377	4011 CRESCENT PARK DR	RIVERVIEW	FL	33578	RECEPT PHARMACY LP
PMP	1378	9265 KIRBY DR	HOUSTON	TX	77054	ADVANCED PHARMA INC
PMP	1379	8337 S PARK CIRCLE	ORLANDO	FL	32819	WALGREENS.COM INC
PMP	1380	829 SPRUCE ST STE 100	PHILADELPHIA	PA	19107	MADAME RX LLC
PMP	1381	2901 KINWEST PKWY #350	IRVING	TX	75063	PRIME THERAPEUTICS SPECIALTY PHARMACY LLC
PMP	1382	8350 S RIVER PKWY	TEMPE	AZ	85284	WALGREENS MAIL SERVICE LLC
PMP	1383	25301 INTERSTATE 45 N STE B	THE WOODLANDS	TX	77380	CONCEPTION PHARMACY LLC
PMP	1384	4227 S HIGHLAND DR #6	HOLLADAY	UT	84124	HRX HHARMACY LLC
PMP	1385	3616 N FRY RD #220	KATY	TX	77449	MILU LLC
PMP	1386	11301 FALLBROOK DR #124	HOUSTON	TX	77065	J&C RX LLC